Theravance Biopharma, Inc. (TBPH) Financials
TBPH Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 382.0 million | 169.0 million |
2023-09-30 | 413.6 million | 167.5 million |
2023-06-30 | 446.6 million | 166.5 million |
2023-03-31 | 538.6 million | 168.0 million |
TBPH Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -1.5 million | 5.8 million |
2023-09-30 | -2.5 million | 6.3 million |
2023-06-30 | -13.3 million | 6.3 million |
2023-03-31 | -12.2 million | 7.0 million |
TBPH Net Income
No data available :(
TBPH Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 102.4 million | - | 49.2 million |
2023-09-30 | 134.0 million | - | 41.1 million |
2023-06-30 | 167.5 million | - | 42.5 million |
2023-03-31 | 241.3 million | - | 43.8 million |
TBPH Shares Outstanding
TBPH Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 677000 | 8.3 million | 15.8 million | - |
2023-09-30 | 21000 | 8.3 million | 16.1 million | - |
2023-06-30 | 852000 | 9.4 million | 19.3 million | - |
2023-03-31 | 938000 | 14.6 million | 19.2 million | - |
TBPH Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 17.6 million | 4.3 million |
2023-09-30 | 15.7 million | 1.3 million |
2023-06-30 | 13.7 million | 1.3 million |
2023-03-31 | 10.4 million | 1.7 million |
TBPH
Price: $9.46
52 week price:
Earnings Per Share: -1.00 USD
P/E Ratio: -8.64
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 260600
Ebitda: -62.9 millionMarket Capitalization: 450.8 million